James R Edwards

Summary

Affiliation: University of Oxford
Country: UK

Publications

  1. doi request reprint Silent information regulator (Sir)T1 inhibits NF-κB signaling to maintain normal skeletal remodeling
    James R Edwards
    Vanderbilt Center for Bone Biology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN 37232, USA
    J Bone Miner Res 28:960-9. 2013
  2. ncbi request reprint Osteoclasts: malefactors of disease and targets for treatment
    James R Edwards
    Institute of Musculoskeletal Sciences, Botnar Research Centre, University of Oxford, Oxford OX3 7LD, United Kingdom
    Discov Med 13:201-10. 2012
  3. doi request reprint Advances in osteoclast biology: old findings and new insights from mouse models
    James R Edwards
    Institute of Musculoskeletal Sciences, University of Oxford, Nuffield Orthopedic Center, Windmill Road, Oxford OX3 7LD, UK
    Nat Rev Rheumatol 7:235-43. 2011
  4. pmc Osteoclasts in multiple myeloma are derived from Gr-1+CD11b+myeloid-derived suppressor cells
    Junling Zhuang
    Department of Medicine and Pharmacology, Vanderbilt University Medical Center, Nashville, Tennessee, United States of America
    PLoS ONE 7:e48871. 2012
  5. pmc Host-derived adiponectin is tumor-suppressive and a novel therapeutic target for multiple myeloma and the associated bone disease
    Jessica A Fowler
    Vanderbilt Center for Bone Biology, Department of Cancer Biology, Vanderbilt University, Nashville, TN, USA
    Blood 118:5872-82. 2011
  6. doi request reprint Advances in the biology of bone metastasis: how the skeleton affects tumor behavior
    Julie A Sterling
    Center for Bone Biology, Vanderbilt University, Nashville, TN, USA
    Bone 48:6-15. 2011
  7. doi request reprint Inhibition of TGF-β signaling by 1D11 antibody treatment increases bone mass and quality in vivo
    James R Edwards
    Vanderbilt Center for Bone Biology, Vanderbilt University Medical Center, Nashville, TN 37232, USA
    J Bone Miner Res 25:2419-26. 2010
  8. pmc Increasing Wnt signaling in the bone marrow microenvironment inhibits the development of myeloma bone disease and reduces tumor burden in bone in vivo
    Claire M Edwards
    Department of Cancer Biology, Vanderbilt Center for Bone Biology, Vanderbilt University, Nashville, TN 37232, USA
    Blood 111:2833-42. 2008
  9. ncbi request reprint Lymphatics and bone
    James R Edwards
    Department of Pathology, Nuffield Department of Orthopaedic Surgery, University of Oxford, Nuffield Orthopaedic Centre, Oxford, OX3 7LD, UK
    Hum Pathol 39:49-55. 2008
  10. ncbi request reprint The osteoclast-not always guilty
    Gregory R Mundy
    Vanderbilt Center for Bone Biology, Vanderbilt University Medical Center, Nashville, TN 37232 0575, USA
    Cell Metab 6:157-9. 2007

Collaborators

Detail Information

Publications14

  1. doi request reprint Silent information regulator (Sir)T1 inhibits NF-κB signaling to maintain normal skeletal remodeling
    James R Edwards
    Vanderbilt Center for Bone Biology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN 37232, USA
    J Bone Miner Res 28:960-9. 2013
    ..These findings support the notion that SirT1 is a genetic determinant of bone mass, acting in a cell-autonomous manner in both osteoblasts and osteoclasts, through control of NF-κB and bone cell differentiation...
  2. ncbi request reprint Osteoclasts: malefactors of disease and targets for treatment
    James R Edwards
    Institute of Musculoskeletal Sciences, Botnar Research Centre, University of Oxford, Oxford OX3 7LD, United Kingdom
    Discov Med 13:201-10. 2012
    ..This review will summarize current literature describing normal and pathological osteoclast biology and highlight the benefits of osteoclast-targeted therapy to combat skeletal disorders...
  3. doi request reprint Advances in osteoclast biology: old findings and new insights from mouse models
    James R Edwards
    Institute of Musculoskeletal Sciences, University of Oxford, Nuffield Orthopedic Center, Windmill Road, Oxford OX3 7LD, UK
    Nat Rev Rheumatol 7:235-43. 2011
    ....
  4. pmc Osteoclasts in multiple myeloma are derived from Gr-1+CD11b+myeloid-derived suppressor cells
    Junling Zhuang
    Department of Medicine and Pharmacology, Vanderbilt University Medical Center, Nashville, Tennessee, United States of America
    PLoS ONE 7:e48871. 2012
    ..Collectively, these data provide in vitro and in vivo evidence that tumor-induced MDSCs exacerbate cancer-associated bone destruction by directly serving as osteoclast precursors...
  5. pmc Host-derived adiponectin is tumor-suppressive and a novel therapeutic target for multiple myeloma and the associated bone disease
    Jessica A Fowler
    Vanderbilt Center for Bone Biology, Department of Cancer Biology, Vanderbilt University, Nashville, TN, USA
    Blood 118:5872-82. 2011
    ..Furthermore, we have established the potential therapeutic benefit of increasing adiponectin for the treatment of myeloma and the associated bone disease...
  6. doi request reprint Advances in the biology of bone metastasis: how the skeleton affects tumor behavior
    Julie A Sterling
    Center for Bone Biology, Vanderbilt University, Nashville, TN, USA
    Bone 48:6-15. 2011
    ..Taken together, these continually emerging areas of study suggest new potential pathways important in the pathogenesis of bone metastasis and potential areas for targeting therapeutics...
  7. doi request reprint Inhibition of TGF-β signaling by 1D11 antibody treatment increases bone mass and quality in vivo
    James R Edwards
    Vanderbilt Center for Bone Biology, Vanderbilt University Medical Center, Nashville, TN 37232, USA
    J Bone Miner Res 25:2419-26. 2010
    ....
  8. pmc Increasing Wnt signaling in the bone marrow microenvironment inhibits the development of myeloma bone disease and reduces tumor burden in bone in vivo
    Claire M Edwards
    Department of Cancer Biology, Vanderbilt Center for Bone Biology, Vanderbilt University, Nashville, TN 37232, USA
    Blood 111:2833-42. 2008
    ....
  9. ncbi request reprint Lymphatics and bone
    James R Edwards
    Department of Pathology, Nuffield Department of Orthopaedic Surgery, University of Oxford, Nuffield Orthopaedic Centre, Oxford, OX3 7LD, UK
    Hum Pathol 39:49-55. 2008
    ..These findings also suggest that lymphangiogenesis is not involved in the disease progression of most primary bone tumors and that carcinomatous metastasis to bone does not occur via lymphatics...
  10. ncbi request reprint The osteoclast-not always guilty
    Gregory R Mundy
    Vanderbilt Center for Bone Biology, Vanderbilt University Medical Center, Nashville, TN 37232 0575, USA
    Cell Metab 6:157-9. 2007
    ....
  11. ncbi request reprint Osteoclast differentiation and bone resorption in multicentric reticulohistiocytosis
    Iannis E Adamopoulos
    Department of Pathology, University of Oxford, OX3 7LD Oxford, UK
    Hum Pathol 37:1176-85. 2006
    ..Inhibitors of osteoclast formation and resorption activity may be of use in preventing the severe joint destruction that commonly occurs in MR...
  12. ncbi request reprint Aging mechanisms in arthritic disease
    Pradeep K Sacitharan
    Botnar Research Centre, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford OX3 7LD, United Kingdom
    Discov Med 14:345-52. 2012
    ..As a significant global link exists between aging and the onset of arthritis, this review will consider whether factors known to affect lifespan may also play a role in arthritic disease...
  13. pmc Activation of NF-kappa B signaling promotes growth of prostate cancer cells in bone
    Renjie Jin
    Vanderbilt Prostate Cancer Center and Department of Urologic Surgery, Vanderbilt University Medical Center, Nashville, Tennessee, USA
    PLoS ONE 8:e60983. 2013
    ....
  14. doi request reprint PTH-related peptide (PTHrP) in hypercalcemia
    Gregory R Mundy
    Vanderbilt Center for Bone Biology, 1235 Medical Research Building IV, Nashville, TN 37232 0575, USA
    J Am Soc Nephrol 19:672-5. 2008
    ....